Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J GOLDSTEIN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1063410645
CMS profile
2193
Location
GREAT NECK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$267.73

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $267.73 2

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
INTUITIVE SURGICAL, INC. $267.73 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J GOLDSTEIN

NPI 1063410645 · CMS profile ID 2193

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

GREAT NECK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL J GOLDSTEIN, NPI 1063410645, CMS profile ID 2193, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1063410645?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $267.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
INTUITIVE SURGICAL, INC. $248.7310/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236646290 CMS
INTUITIVE SURGICAL, INC. $19.0010/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236646292 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $622.74 34
PY2020 $554.05 32
PY2021 $303.05 16
PY2022 $155.50 9
PY2023 $187.37 4
PY2025 $267.73 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $88,071.47 22
PY2023 Principal investigator $169,779.57 14
PY2022 Principal investigator $32,010.78 12
PY2021 Recipient $3,971.40 2
PY2021 Principal investigator $162,998.92 79
PY2020 Principal investigator $489,931.11 140
PY2019 Recipient $883.66 5
PY2019 Principal investigator $583,175.74 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

140 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $2,128.80 12/31/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721314707
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $800.00 12/23/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 749682387
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,000.00 12/18/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-301 No dispute reported 06/30/2026 749681243
Principal investigator 1 Allergan, Inc. $700.00 12/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721313533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,394.10 12/15/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737094229
Principal investigator 1 Braintree Laboratories, Inc. $200.00 12/14/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 751303985
Principal investigator 1 Braintree Laboratories, Inc. $6,500.00 12/14/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-302 No dispute reported 06/30/2026 751303987
Principal investigator 1 Allergan, Inc. $1,500.00 12/01/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721310045
Principal investigator 1 Allergan, Inc. $1,500.00 12/01/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721310209
Principal investigator 1 Braintree Laboratories, Inc. $100.00 11/30/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 751303967
Principal investigator 1 Braintree Laboratories, Inc. $11,686.95 11/30/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 751303969
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $150.00 11/25/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749678927
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $62.50 11/25/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749678932
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,155.60 11/24/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737093073
Principal investigator 1 Allergan, Inc. $1,045.00 11/20/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721309443
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,600.00 11/20/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
STUDY TO ASSESS THE EFFICACY OF VLY-686 IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128823
Principal investigator 1 Adare Pharmaceuticals, Inc. $1,788.48 11/19/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) No dispute reported 06/30/2026 750511715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 11/12/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 724478905
Principal investigator 1 Allergan, Inc. $5,267.10 11/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721307517
Principal investigator 1 Braintree Laboratories, Inc. $200.00 11/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 751303883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,497.00 11/05/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 724478611
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $35,329.00 10/30/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749677639
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 10/30/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749678921
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $250.00 10/30/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749680105
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $250.00 10/30/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749680109
Principal investigator 1 Braintree Laboratories, Inc. $9,817.20 10/26/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 751303875
Principal investigator 1 Allergan, Inc. $1,011.75 10/23/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721305155
Principal investigator 1 Allergan, Inc. $1,011.75 10/23/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721305157
Principal investigator 1 Braintree Laboratories, Inc. $7,290.45 10/19/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 751303791
Principal investigator 1 Adare Pharmaceuticals, Inc. $500.00 10/15/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) No dispute reported 06/30/2026 750511713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $432.10 10/15/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 724477087
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,466.80 10/14/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737090029
Principal investigator 1 Allergan, Inc. $150.00 10/05/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721301517
Principal investigator 1 Allergan, Inc. $250.00 10/05/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721301603
Principal investigator 1 Allergan, Inc. $150.00 10/01/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721301213
Principal investigator 1 Allergan, Inc. $327.00 09/29/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721301009
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 09/29/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737089513
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721299433
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721299465
Principal investigator 1 Allergan, Inc. $315.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721299891
Principal investigator 1 Allergan, Inc. $150.00 09/17/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721298265
Principal investigator 1 Allergan, Inc. $140.00 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721296221
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749677621
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $137.50 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749677627
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $16.97 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749680089
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $800.00 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749680095
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $120.00 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749681237
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737087713
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 09/09/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737087715
Principal investigator 1 Allergan, Inc. $327.00 09/08/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721295833
Principal investigator 1 Allergan, Inc. $955.00 08/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721293545
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,700.00 08/26/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749682383
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $72.50 08/25/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
MCP-103-205 No dispute reported 06/30/2026 749684727
Principal investigator 1 Allergan, Inc. $420.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721292231
Principal investigator 1 Allergan, Inc. $385.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721292287
Principal investigator 1 Allergan, Inc. $327.00 08/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721292841
Principal investigator 1 Allergan, Inc. $3,055.50 08/20/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721291715
Principal investigator 1 Allergan, Inc. $1,159.00 08/19/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721291549
Principal investigator 1 Allergan, Inc. $1,064.00 08/18/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721290959
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $700.00 08/18/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
MCP-103-205 No dispute reported 06/30/2026 749677633
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 07/24/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749684721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 07/23/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 724471585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,813.88 07/23/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 724471593
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $48,384.63 07/22/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749680099
Principal investigator 1 Allergan, Inc. $140.00 07/08/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721283119
Principal investigator 1 Allergan, Inc. $2,037.00 06/23/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721281425
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,350.00 06/19/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749677642
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,350.00 06/19/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749680113
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $250.00 06/19/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749683527
Principal investigator 1 Allergan, Inc. $2,232.50 06/15/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721279483
Principal investigator 1 Allergan, Inc. $385.00 05/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721277073
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 05/13/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749684731
Principal investigator 1 Braintree Laboratories, Inc. $600.00 05/08/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 751303717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,186.80 05/05/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737078407
Principal investigator 1 Allergan, Inc. $385.00 04/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721272535
Principal investigator 1 Allergan, Inc. $3,914.00 04/23/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721272583
Principal investigator 1 Allergan, Inc. $1,168.50 04/20/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721271291
Principal investigator 1 Allergan, Inc. $3,372.50 04/16/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721270663
Principal investigator 1 Allergan, Inc. $12,236.00 04/16/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721270665
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $83,192.50 04/15/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749683525
Principal investigator 1 Braintree Laboratories, Inc. $3,500.00 03/27/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI4900-301 No dispute reported 06/30/2026 751303661
Principal investigator 1 Adare Pharmaceuticals, Inc. $5,650.00 03/26/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) No dispute reported 06/30/2026 750511707
Principal investigator 1 Allergan, Inc. $371.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS (DG) No dispute reported 06/30/2026 721267171
Principal investigator 1 Allergan, Inc. $1,092.50 03/25/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721266933
Principal investigator 1 Allergan, Inc. $1,168.50 03/24/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721266699
Principal investigator 1 Allergan, Inc. $1,018.50 03/24/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721266759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.10 03/24/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737075219
Principal investigator 1 Braintree Laboratories, Inc. $1,500.00 03/20/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 751303633
Principal investigator 1 Allergan, Inc. $2,000.00 03/18/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721265303
Principal investigator 1 Allergan, Inc. $1,976.00 03/16/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) No dispute reported 06/30/2026 721264489
Principal investigator 1 Adare Pharmaceuticals, Inc. $700.00 03/12/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH
Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE) No dispute reported 06/30/2026 750512041
Principal investigator 1 Allergan, Inc. $70.00 03/11/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721263211
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 03/11/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749677657
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 03/11/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749682401
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 03/11/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749684753
Principal investigator 1 Allergan, Inc. $800.00 03/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721263071
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 03/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
ORAL BUDESONIDE SUSPENSION (OBS) IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS: DB, MAINTENANCE No dispute reported 06/30/2026 737073785
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $250.00 03/06/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749680119
Principal investigator 1 Allergan, Inc. $494.70 03/04/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721261965
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,050.00 03/04/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749684747
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 03/03/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737073239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,466.80 03/03/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737073241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 03/03/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737073243
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $70.00 03/03/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737073245
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,100.00 02/26/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749677651
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $800.00 02/26/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749681259
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $19.40 02/26/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749681265
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $650.00 02/26/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749682397
Principal investigator 1 Allergan, Inc. $86.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721260079
Principal investigator 1 Allergan, Inc. $700.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721260133
Principal investigator 1 Allergan, Inc. $3,244.25 02/25/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721260847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,275.00 02/25/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION (BOS) FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 737072683
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,519.20 02/25/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737072733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $175.00 02/20/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RSRCH GRP LLP
A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) No dispute reported 06/30/2026 724455501
Principal investigator 1 Allergan, Inc. $400.00 02/19/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721258377
Principal investigator 1 Allergan, Inc. $400.00 02/18/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721258283
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,275.00 02/18/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
ORAL BUDESONIDE SUSPENSION (OBS) IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS: DB, MAINTENANCE No dispute reported 06/30/2026 737072205
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $186.00 02/18/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
ORAL BUDESONIDE SUSPENSION (OBS) IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS: DB, MAINTENANCE No dispute reported 06/30/2026 737072207
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,225.00 02/13/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
MCP-103-205 No dispute reported 06/30/2026 749677647
Principal investigator 1 Allergan, Inc. $327.00 02/04/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 721255723
Principal investigator 1 Allergan, Inc. $400.00 02/03/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721254941
Principal investigator 1 Allergan, Inc. $500.00 02/03/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721254945
Principal investigator 1 Allergan, Inc. $115.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 721252815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,186.80 01/28/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737068773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 01/28/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 737068775
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $4,743.75 01/24/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
MCP-103-205 No dispute reported 06/30/2026 749685929
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,100.00 01/22/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
MCP-103-312 No dispute reported 06/30/2026 749681249
Principal investigator 1 Allergan, Inc. $1,018.50 01/20/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) No dispute reported 06/30/2026 721248927
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $10,000.00 01/17/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749681253
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $160.00 01/17/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749682391
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $76,648.75 01/17/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
C3718-302 No dispute reported 06/30/2026 749684741
Principal investigator 1 Allergan, Inc. $1,634.00 01/15/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721247699
Principal investigator 1 Allergan, Inc. $1,615.00 01/14/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 721247497
Principal investigator 1 Braintree Laboratories, Inc. $9,400.00 01/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 751303599
Principal investigator 1 Braintree Laboratories, Inc. $9,400.00 01/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 751303601
Principal investigator 1 Braintree Laboratories, Inc. $9,400.00 01/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 751303603
Principal investigator 1 Braintree Laboratories, Inc. $7,050.00 01/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 751303605
Principal investigator 1 Braintree Laboratories, Inc. $9,400.00 01/10/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP
BLI800-491 No dispute reported 06/30/2026 751303621
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,170.00 01/07/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
MCP-103-205 No dispute reported 06/30/2026 749684735
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $950.00 01/02/2020 Non-covered Recipient Entity
LONG ISLAND GASTROINTESTINAL RESEARCH GROUP LLP
ORAL BUDESONIDE SUSPENSION (OBS) IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS: DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 737066487